Articles tagged with Lymphoma
A recent study found that antibiotic resistance rates for Helicobacter pylori are decreasing in European countries. The use of three antibiotics over 10-14 days resulted in success rates of over 90%. The researchers hope to reduce antibiotic consumption to prevent further resistance.
Researchers found that higher lymphoma volume at diagnosis was associated with increased risk of recurrence. This could lead to improved patient outcomes by selecting the most appropriate treatment. The study also explored PET-based measures of initial disease burden, which may help predict patients' risk of recurrence.
A study found that younger B-cell non-Hodgkin lymphoma survivors are at a higher risk of developing age-related diseases, including renal failure, pneumonia, and nutritional deficiencies. The research suggests that aggressive treatment regimens may be the underlying factor contributing to this increased risk.
Cancer cells alter the large blood vessels in lymph nodes, disrupting their function and allowing tumor cells to evade attack by the immune system. The researchers identified identical findings in mice and humans, providing a deeper understanding of how lymphomas protect themselves from the body's defenses.
A team of scientists developed a drug-like molecule that can counteract the effects of mutated epigenetic regulators, which are known to drive certain types of cancer. The molecule targets the 'reader' CBX8, which is critical for the proliferation of cancer cells, but more dispensable in healthy cells.
A new imaging technique using PET/MR and a PET tracer directed against CXCR4 shows high accuracy in detecting MALT lymphomas of the stomach, potentially reducing the need for repeated gastroscopies. The study found that [68Ga]Pentixafor PET/MR achieved 97% accuracy in detecting tumours compared to gastroscopy.
A modified chemotherapy regimen for Burkitt lymphoma has been developed, combining CODOX-M and IVAC with rituximab, to reduce toxicity and improve survival rates. The study found a higher overall survival rate and lower frequency of severe side effects compared to standard regimens.
Researchers at the University of Southampton have identified a unique change in B cells that allows them to receive signals from molecules called lectins, enabling tumor growth. This discovery could pave the way for new treatments and early cancer detection methods.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
A new study by CNIO researchers has found that blocking the RagC protein's signals can delay the onset of follicular lymphoma in animal models. The strategy may also be effective in treating autoimmune diseases.
The RESILIENCE project seeks to prevent anthracycline-induced cardiotoxicity in cancer patients through remote ischaemic preconditioning, with over 600 patients enrolled in a randomised clinical trial. Cardiac function will be evaluated using state-of-the-art cardiac magnetic resonance imaging.
A new class of drugs inhibiting the SOX 11 oncogene has been discovered by researchers at Mount Sinai, showing promising results in treating mantle cell lymphoma. The discovery could lead to new therapies for a disease resistant to existing treatments.
A new preclinical study from the University of Texas MD Anderson Cancer Center found that cord blood-derived NK cells combined with AFM13 displayed potent anti-tumor activity against CD30+ lymphoma cells. The therapy showed improved tumor control and survival in animal models with minimal side effects.
A phase 2 clinical trial found that brentuximab vedotin achieved excellent outcomes in high-risk pediatric Hodgkin lymphoma patients, with a three-year survival rate of 99% and reduced radiation exposure. The targeted therapy also minimized side effects, particularly neuropathy.
A new study by Uppsala University found that unmarried patients and those with low educational attainment are less likely to be treated with a stem-cell transplantation for mantle cell lymphoma. The study suggests that this may result in poorer survival rates.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab. In a non-Hodgkin's lymphoma mouse model, the treatment substantially increased rituximab binding and antibody-dependent cellular cytotoxicity activity, resulting in significant tumor growth delay.
Researchers at Josep Carreras Leukaemia Research Institute discovered a marker predicting aggressive clinical course in Hodgkin's lymphoma patients. The marker allows identifying patients with poor evolution, enabling early intervention and improved treatment outcomes.
A phase III trial showed rituximab significantly improves the three-year survival rate for pediatric patients with advanced B-cell non-Hodgkin lymphoma, decreasing treatment failures by 70 percent.
A new immunotherapeutic agent has been shown to significantly improve treatment outcomes for children and adolescents with advanced non-Hodgkin lymphoma, particularly Burkitt lymphoma. The agent, rituximab, in combination with chemotherapy, has a cure rate of over 95% and reduces the risk of disease progression by up to 70%.
Researchers discovered that tumors in lymph nodes are distinct from solid tumors, with a unique pattern of branching and signaling pathways. They identified VEGF-C as the primary driver of angiogenesis in early stages of lymphoma, which can be targeted to slow tumor growth.
A new study reveals that MNT is required for the survival of MYC-driven lymphoma cells, suggesting a promising new approach for treating this type of cancer. Inhibiting MNT may also make tumours more susceptible to other drugs, offering hope for improved treatments.
A randomized, double-blind trial compared the safety and efficacy of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma. F14512 demonstrated significant antitumor activity and clinical benefits, particularly in P-glycoprotein overexpressing lymphomas.
A new analysis reveals that donor stem cell transplantation following PD-1 treatment is generally safe and produces good outcomes for patients with Hodgkin lymphoma. Post-transplant treatment with cyclophosphamide may also lead to improved results, reducing rates of acute GVHD and relapse.
A new study from Georgetown University Medical Center found that 38 patients with follicular lymphoma who were in remission for at least two years did not show any evidence of the disease in their blood. This suggests that these patients may be disease-free and could have a lifelong disease status.
Researchers discovered that chronic inflammatory processes in aging brains lead to lymphoma cells being retained in the brain tissue instead of being released back into the blood. The NF-kappaB signaling pathway and CCL19 play a crucial role in this process, allowing lymphoma cells to multiply and develop tumors.
Follicular lymphoma originates from mutations in RagC gene on mTOR signalling pathway, affecting B cell growth. Rapamycin treatment delays progression and prolongs survival in mice with RagC mutations.
A study found a statistically significant association between BRCA2 mutations and increased risk of non-Hodgkin lymphoma in children. Additionally, BRCA2 mutations were not associated with an increased risk of Hodgkin lymphoma.
Researchers at UNC Lineberger Comprehensive Cancer Center discovered a hyperactive cell signal contributing to tumor growth in aggressive blood cancer. They developed an experimental therapeutic compound, UNC3810A, that targeted and slowed tumor growth by blocking the hyperactive Tyro3 protein.
Researchers discovered MYC's new roles in cancer cell efficiency and protein production. High MYC levels stimulate specific mRNAs translation into respiratory complex proteins, fueling growth. This study reveals MYC regulates metabolic enzymes and immune receptors in lymphoma cells.
Researchers from Johns Hopkins Medicine found a distinct subtype of primary central nervous system lymphoma suitable for surgical removal, offering improved outcomes and potential cure rates. The study suggests a shift in treatment approach, moving away from traditional biopsy, radiotherapy, and high-dose chemotherapy.
Researchers identified LTA as a key player in Hodgkin's lymphoma progression, activating NF-kB and promoting cancer cell proliferation. This discovery suggests LTA could be a target for new treatment strategies.
Researchers from Colorado State University found that dogs with omega-3 fatty acid supplements or hypothyroidism are less likely to develop T-zone lymphoma. The study also revealed a link between defective genes and the disease, suggesting potential new avenues for research and prevention.
Early results from the UNITY-NHL phase II clinical trial show umbralisib to be highly active against relapsed/refractory marginal zone lymphoma, with a 55% partial or complete response rate and 71% progression-free survival at 12 months.
A Phase II trial at MD Anderson Cancer Center showed umbralisib to be an effective treatment for patients with relapsed marginal zone lymphoma, achieving a 55% partial or complete response rate. The drug was well-tolerated, with a 71% progression-free survival after one year.
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a distinct form of cancer linked to textured breast implants. Clear guidelines formalize treatment strategy, recommending surgical techniques like stepwise en bloc resection for complete oncologic resection and removal of involved lymph nodes.
Survivors of childhood Hodgkin lymphoma are at a significantly increased risk of developing various types of solid tumors over the long term. Certain subgroups of patients have an even higher risk, and these findings may help refine guidelines for cancer screening in Hodgkin lymphoma survivors.
The Paul G. Allen Frontiers Group has awarded $13.5 million to 10 researchers studying lymphoma, neuroimmunology, nuclear biophysics, and brain cell function. These studies aim to shed light on Alzheimer's disease and develop new treatments for blood cancers.
A phase III trial shows duvelisib significantly extends progression-free survival, offering a new treatment option for patients with relapsed or treatment-resistant CLL and SLL. The therapy also works well in sub-group analyses for hardest-to-treat cases with limited options.
Researchers have developed a new drug that targets EBV-positive tumors and inhibits tumor development and metastases for EBV-related lymphomas. The findings suggest the drug may be useful in treating malignancies in EBV-positive patients.
Researchers at Georgia State University have developed a blood test that can diagnose two types of cancer, lymphoma and melanoma, using mid-infrared spectroscopy. The test has shown promising results in differentiating between healthy mice and those with tumorous conditions, and could potentially be used for screening humans.
Researchers found that higher physical activity prior to diagnosis and increased activity after diagnosis significantly improved overall and lymphoma-specific survival. Decreased perception of physical activity also led to poorer outcomes.
A new study identifies six genetic changes linked to Hodgkin lymphoma, a cancer of the immune system. The research offers important clues for understanding both lymphoma and autoimmune diseases.
A Cancer Research UK-funded study found that combining anti-CD27 and anti-CD20 antibodies increases life expectancy in mice with cancer by nearly doubling the median survival time. The combination recruits more immune cells and enhances their ability to destroy cancer cells, offering a promising new approach to treating lymphoma.
The University of Iowa/Mayo Clinic Lymphoma SPORE is one of the nation's longest-standing programs, funded for five years at $12.4 million. The team conducts translational and clinical studies to develop new approaches to lymphoma prevention, detection, and treatment.
Researchers discovered that the Sestrin1 gene is frequently missing or malfunctioning in follicular lymphoma patients, leading to tumor growth and poor prognosis. The study found that targeting this gene can suppress tumors and improve treatment efficacy, offering hope for new therapies.
Cancer researchers at GW Cancer Center investigate how mantle cell lymphoma cells develop resistance to targeted therapy Ibrutinib. They found that the cells adapt by activating alternative pathways, such as PI3K-AKT-mTOR, allowing them to continue progressing.
Research found that Hodgkin lymphoma survivors who received chest irradiation had significantly more multi-vessel coronary artery disease and higher segment involvement scores compared to controls. The study suggests that patients should be screened for coronary artery disease at regular intervals after irradiation.
Researchers at Osaka University discovered how specific genes regulate B cell cycling in germinal centers. They found that Foxo1 promotes B cell proliferation, but its activation is associated with lymphomas. Reviving BATF levels recovered the proliferation of Foxo1-deficient B cells.
Scientists have discovered that GSK3 plays a crucial role in controlling B cell metabolism, adapting to varying energy needs. The study found that GSK3 limits metabolic activity in circulating B cells while slowing glycolysis and production of mitochondria in proliferating B cells in germinal centers.
Researchers uncover disparate evolutionary trajectories and mutational profiles driving follicular lymphoma's transformation and early progression. The study highlights key genes and biological processes associated with these events, offering a basis for future research on prognostic assays and treatment strategies.
Researchers found GALV retrovirus was likely transmitted to gibbons from rodents by medical researchers working on human diseases, causing a serious outbreak in the 1960s and 1970s. No evidence of ongoing infection or threat found in current captive gibbon populations.
HIV-infected patients with chronic HBV and HCV coinfection are at a higher risk for non-Hodgkin's lymphoma, a leading cause of AIDS-related deaths. The study found that the incidence rate is 10 times higher in HIV-infected persons compared to the general population.
A large-scale migrant cohort study found that being born in Israel significantly increases the risk of nodular sclerosis HL, with elevated risks also observed among women, those born more recently, and taller stature. The study suggests exposure to unidentified elements of the Israeli environment may contribute to the disease's etiology.
Researchers have developed a new approach to limit side effects of stem cell transplants by stimulating the formation of regulatory T cells in recipients. Pretreating mice with STAR2 protein protected them from developing GvHD, while donor-derived cells retained their ability to kill recipient's tumor cells.
Researchers at Université de Genève have developed an antibody that blocks the migration of cancer cells, preventing their spread and proliferation. The 'H225' antibody reduces cancerous cell transit into organs by over 50% and limits cell proliferation, offering a promising new therapeutic strategy against lymphoma.
Researchers developed a measurement called cumulative burden to capture chronic disease in childhood cancer survivors, showing that Hodgkin lymphoma patients have more cardiovascular conditions and severe heart problems than adults without childhood cancer. This method should aid efforts to reduce and better manage late effects of canc...
A Phase II trial suggests that brentuximab vedotin can cure some patients with Hodgkin lymphoma who have relapsed despite previous therapies. The study reports that 13 of 34 patients who achieved complete remission remained disease-free for over five years.
A UCLA study found that anti-inflammatory gut bacteria can slow or stop the development of certain types of cancer. Researchers discovered that a specific bacterium, Lactobacillus johnsonii 456, reduced gene damage and inflammation in mice with cancer, leading to a lower risk of tumor formation.
A new study reveals significant racial disparities in treatment for patients with HIV and Hodgkin lymphoma, with black patients facing higher rates of non-treatment. Despite effective treatment options, doctors note that socioeconomic factors and lack of access to care may contribute to these disparities.
Mutations in follicular lymphoma have revealed new molecular targets for potential treatments, according to researchers at Queen Mary University of London. The mutations identified allow tumours to evade normal restrictions on growth, making existing therapies less effective.